GPA
NVO

Guidance Point Advisors’s Novo Nordisk NVO Stock Holding History

Guidance Point Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-548
Closed -$26K – 301
2021
Q3 		$26K Buy
+548
New +$26.5K 0.01% 192

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Guidance Point Advisors's NVO Position: Q4 2021 in Review

Guidance Point Advisors sold out of Novo Nordisk (NVO) in Q4 2021, closing a stake of 548 shares — an estimated $26K sold.

Guidance Point Advisors first reported a position in NVO in Q3 2021 and held it in 1 quarter. The position peaked at $26K in Q3 2021. 886 funds tracked by Wall St. Rank hold NVO as of Q4 2021.

  • Guidance Point Advisors reported no remaining Novo Nordisk position as of Q4 2021 after selling out during the quarter.
  • Guidance Point Advisors sold 548 Novo Nordisk shares in Q4 2021, an estimated $26K.
  • Guidance Point Advisors first reported a position in Novo Nordisk in Q3 2021 and held it in 1 quarter.
  • Guidance Point Advisors's Novo Nordisk position peaked at $26K in Q3 2021.
  • 886 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2021.

Based on Guidance Point Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.